Management of Early Relapse, How to Navigate the Choices

Treatment of relapsed and/or refractory multiple myeloma (RRMM) is always a challenge for the hematologist. Over the last 5 years, a spectrum of novel therapies with different mechanisms of action, including second generation proteasome inhibitors (carfilzomib and ixazomib), third-generation immunomodulatory drugs (pomalidomide), a histone deacetylase inhibitor (panobinostat) and monoclonal antibodies (mAbs) (elotuzumab and daratumumab) has transformed our approach to the treatment of patients with RRMM.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Source Type: research